SRTA

Strata Critical Medical, Inc. (SRTA) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This filing covers the quarterly period ended March 31, 2026. Strata Critical Medical, Inc. operates as a time-critical logistics and medical services provider for the U.S. healthcare industry, focusing on organ transplant logistics and clinical services. The company operates two reportable segments: Logistics (air and ground transport) and Clinical (organ recovery, perfusion, and cardiac care). The reporting period reflects the full impact of the Keystone Perfusion Services acquisition (closed September 2025) and the complete divestiture of the Passenger business (closed August 2025), which is now reported as discontinued operations.

Key Financial Metrics

Note: Net income includes non-operating gains from fair value adjustments of warrant liabilities and contingent consideration assets.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 87.4% to $67.4 million, driven by a 32.4% increase in Logistics revenue and the addition of $19.8 million in Clinical revenue from the Keystone acquisition.
• Profitability: The company reported a net income of $2.2 million compared to a net loss of $3.5 million in the prior year. This turnaround was significantly aided by $5.4 million in non-operating income (fair value changes of warrants and contingent assets).
• Operating Performance: Operating loss from continuing operations narrowed from $5.7 million to $3.0 million. Adjusted EBITDA improved dramatically to $6.4 million from $0.4 million.
• Liquidity: Cash and cash equivalents increased to $58.7 million, up from $31.0 million at year-end 2025, primarily due to the maturity of held-to-maturity investments ($30.5 million proceeds) and strong operating cash flow ($3.9 million).
• Discontinued Operations: The Passenger business divestiture resulted in a net loss of $0.2 million for the quarter, primarily due to a post-closing working capital adjustment, compared to a $1.9 million loss in the prior year.

Outlook, Risks, and Unusual Items

• Unusual Items: The income statement includes significant non-cash items: a $1.5 million gain from the change in fair value of warrant liabilities and a $3.4 million gain from the change in fair value of assets/liabilities (primarily contingent consideration related to the Passenger sale and Keystone acquisition).
• Capital Structure: In January 2026, the company secured a $30 million asset-based revolving credit facility (ABL) with JPMorgan Chase, maturing in 2029. No borrowings were outstanding as of March 31, 2026.
• Subsequent Events: On April 30, 2026, the company acquired Ohio Valley Perfusion Associates for approximately $1.0 million in cash.
• Risks: Key risks include dependence on donor organ volumes, reliance on third-party aircraft operators, inflation in fuel and labor costs, and the ability to integrate acquired businesses (Keystone). The company maintains a full valuation allowance on deferred tax assets.
• Guidance: The filing does not provide specific numerical guidance for the full year 2026 but states management anticipates sufficient liquidity to meet operational needs for the next 12 months.

Investor Verification Checklist

• Non-GAAP Reconciliation: Verify the sustainability of the $6.4 million Adjusted EBITDA by reviewing the add-backs for fair value changes ($4.9 million total) and stock-based compensation ($5.0 million).
• Warrant Liability: Monitor the fair value of the $71,000 warrant liability, as fluctuations in the company's stock price will directly impact non-operating income/loss.
• Contingent Consideration: Review the $28.8 million in contingent consideration assets (related to the Passenger sale) and $12.9 million in share-based payment liabilities, as these are subject to fair value remeasurement.
• Keystone Integration: Assess the performance of the Clinical segment ($19.8M revenue, 25% margin) to ensure it meets the earn-out targets required for the remaining $23 million in potential payments.
• Cash Burn vs. Generation: Confirm that the shift from negative to positive operating cash flow ($3.9M) is sustainable as the company scales its owned aircraft fleet and clinical operations.